Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IgA Monoclonal Gammopathy of Undetermined Significance”

4 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 4 results

Early research (Phase 1)Study completedNCT03820817
What this trial is testing

Rifaximin in Patients With Monoclonal Gammopathy

Who this might be right for
IgA Monoclonal GammopathyIgG Monoclonal GammopathyIgM Monoclonal Gammopathy+6 more
Emory University 50
Not applicableLooking for participantsNCT06065852
What this trial is testing

National Registry of Rare Kidney Diseases

Who this might be right for
Adenine Phosphoribosyltransferase DeficiencyAH AmyloidosisAHL Amyloidosis+81 more
UK Kidney Association 35,000
Not applicableActive Not RecruitingNCT04023747
What this trial is testing

Oxford Pre-cancerous Lymphoproliferative Disorders Study

Who this might be right for
Pre-cancerous Lymphoproliferative Disorders
University of Oxford 574
Testing effectiveness (Phase 2)Looking for participantsNCT07209371
What this trial is testing

Rifaximin Versus No Intervention for the Treatment of IgG/IgA (Non-IgM) Monoclonal Gammopathy of Undetermined Significance

Who this might be right for
IgA Monoclonal Gammopathy of Undetermined SignificanceNon-IgM Monoclonal Gammopathy of Undetermined Significance
Fred Hutchinson Cancer Center 50